2 Stocks That Could Capitalize on the GLP-1 Boom

The article highlights CVS Health and Roche as two stocks positioned to benefit from the growing GLP-1 drug market. CVS is leveraging its pharmacy network and low-cost telemedicine services to improve patient access to GLP-1 medications, while Roche is developing promising weight-loss drugs including CT-388, a dual GLP-1/GIP agonist showing strong clinical results. Both companies offer diversified business models beyond GLP-1 to mitigate risks.